An expression silencing system and different uses thereof
CA 2359356 A1 · Owner: Yissum Research Development Company Of The Hebrew University Of Jerusale M · Inventors: Zeitoune-Simovich, Sylvia; Sela, Ilan
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to an expression-silencing system comprising a first DNA construct comprising a nucleotide sequence corresponding to the T7 RNA polymerase gene (T7-pol) which carries an NLS sequence and at least one , promoter and at least one terminator sequence operably linked to the T7-pol; a second DNA construct comprising a T7 promoter sequence (pT7) at least one , targeting sequence downstream to said pT7 and at least one 3' non-translated terminator sequence operably linked to the targeting sequence; which system can, upon its introduction into a cell substantially silence the expression , at the RNA level of a target sequence in the cell in a tissue or organ , regenerated …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed January 16, 2000. No grant is recorded for it in Canada; had it been granted, its 20-year term would have ended January 16, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by January 16, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.